Patents by Inventor Leticia Corrales Pecino

Leticia Corrales Pecino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10545150
    Abstract: The invention provides a method of diagnosis and/or prognosis of lung cancer, the method comprising the steps of: (a) determining the level of a C4 activation fragment in a test sample, and (b) comparing the level of the test sample with the level of a C4 activation fragment detected in a control sample, wherein if the level of C4 activation fragment is higher than the level in a reference control, it is indicative that the subject suffers lung cancer or has a bad prognosis. The present invention further provides methods for determining the risk of suffering from lung cancer as well as for deciding whether to initiate a medical regimen and to determine the efficacy of said medical regimen, based on the determination of a C4 activation fragment. C4 activation fragment, used as marker, confers high sensitivity and specificity to the methods object of the invention.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: January 28, 2020
    Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L.
    Inventors: Daniel Ajona Martínez-Polo, Leticia Corrales Pecino, Luis Montuenga Badía, María José Pajares Villandiego, Rubén Pío Osés
  • Publication number: 20150072361
    Abstract: The invention provides a method of diagnosis and/or prognosis of lung cancer, the method comprising the steps of: (a) determining the level of a C4 activation fragment in a test sample, and (b) comparing the level of the test sample with the level of a C4 activation fragment detected in a control sample, wherein if the level of C4 activation fragment is higher than the level in a reference control, it is indicative that the subject suffers lung cancer or has a bad prognosis. The present invention further provides methods for determining the risk of suffering from lung cancer as well as for deciding whether to initiate a medical regimen and to determine the efficacy of said medical regimen, based on the determination of a C4 activation fragment. C4 activation fragment, used as marker, confers high sensitivity and specificity to the methods object of the invention.
    Type: Application
    Filed: March 20, 2013
    Publication date: March 12, 2015
    Inventors: Daniel Ajona Martínez-Polo, Leticia Corrales Pecino, Luis Montuenga Badía, María José Pajares Villandiego, Rubén Pío Osés